[Microbiome And Gastrointestinal Diseases].

Mikrobiom und gastrointestinale Erkrankungen.

Journal

Deutsche medizinische Wochenschrift (1946)
ISSN: 1439-4413
Titre abrégé: Dtsch Med Wochenschr
Pays: Germany
ID NLM: 0006723

Informations de publication

Date de publication:
07 2019
Historique:
entrez: 17 7 2019
pubmed: 17 7 2019
medline: 30 11 2019
Statut: ppublish

Résumé

For some years, microbiome research has become a thriving topic. The most diverse and hitherto poorly understood connections of interactions of the microbiome with the host body (human) seem to play an important role in the genesis of a wide variety of diseases. This article focuses on the importance of the microbiome in gastrointestinal diseases and presents therapeutic approaches.The intestinal microbiome will not be understood completely for a long time due to the highly complex relationships and variety of different microorganisms. The intestinal microbiome is critically involved in the development of diseases, especially in the development of inflammatory bowel disease. Helicobacter pylori infection is a major risk factor for gastric carcinoma. Esophageal microbiome alterations can cause inflammation and decrease the tone of the lower esophageal sphincter. Inflammation is a crucial pathway for tumorigenesis, it can be caused by the "normal" flora and by pathogenic agents. In the microbiome of the colon, interactions of bacteria, viruses and fungi have a very special status. Good oral/dental status protects against pancreatic carcinoma. Fecal microbiome transfer has become more important in the American guideline. Understanding the processes in the intestinal microbiome provides approaches to new therapies that are likely to exceed our current imagination.

Identifiants

pubmed: 31311044
doi: 10.1055/a-0899-8759
doi:

Types de publication

Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

949-956

Informations de copyright

© Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

Julian Siegel: Keine InteressenkonflikteViola Andresen: Vortrags- und/oder Beratungstätigkeiten: Allergan, Bayer, Falk, Ferring, Hexal, KyowaKirin, 4M-Medical, Sanofi, Schwabe, ShionogiPeter Layer: Abbott, Allergan, Falk, Nordmark

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH